Drug Approval | December 04, 2025
FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software
Here's a development that aims to keep your blood pressure in check. Literally!
The company is excluding data from the affected sites to maintain the study's integrity
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Presbyopia, the age-related loss of near vision, could soon be treated successfully
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Subscribe To Our Newsletter & Stay Updated
